Chimeric Antigen Receptors

Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens.

Also Known As:

Receptors, Chimeric Antigen; Artificial T-Cell Receptors; Chimeric Immunoreceptors; Chimeric T-Cell Receptors; Antigen Receptor, Chimeric; Antigen Receptors, Chimeric; Artificial T Cell Receptors; Chimeric T Cell Receptor; Chimeric T Cell Receptors; Immunoreceptors, Chimeric; Receptor, Chimeric Antigen; Receptor, Chimeric T-Cell; Receptors, Artificial T-Cell; Receptors, Chimeric T-Cell; T-Cell Receptor, Chimeric; T-Cell Receptors, Artificial; T-Cell Receptors, Chimeric; Chimeric Antigen Receptor; Chimeric T-Cell Receptor

Networked: 6553 relevant articles (1010 outcomes, 542 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	June, Carl H: 119 articles (12/2022 - 03/2008)
2.	Dotti, Gianpietro: 81 articles (03/2022 - 11/2005)
3.	Maus, Marcela V: 64 articles (11/2022 - 07/2013)
4.	Grupp, Stephan A: 59 articles (10/2022 - 08/2011)
5.	Gottschalk, Stephen: 52 articles (11/2022 - 06/2007)
6.	Huang, He: 52 articles (01/2022 - 01/2016)
7.	Abken, Hinrich: 51 articles (10/2022 - 10/2007)
8.	Brentjens, Renier J: 48 articles (01/2022 - 09/2007)
9.	Savoldo, Barbara: 48 articles (01/2022 - 06/2007)
10.	Levine, Bruce L: 45 articles (11/2022 - 03/2008)

Related Diseases

1.	Neoplasms (Cancer) 11/19/2020 - "Clinical trials demonstrated that CD19+ chimeric antigen receptor (CAR) T-cells can be highly effective against a number of malignancies. " 01/01/2016 - "The adoptive transfer of T cells expressing anti-CD19 chimeric antigen receptors (CARs) has shown remarkable curative potential against advanced B-cell malignancies, but multiple trials have also reported patient relapses due to the emergence of CD19-negative leukemic cells. " 11/01/2023 - "Chimeric Antigen Receptor (CAR) T-cell therapy is a highly effective treatment for B-cell malignancies but limited in use due to clinically significant hyperinflammatory toxicities. " 07/01/2023 - "Chimeric antigen receptor (CAR-T) cell therapy is highly effective against hematological cancers but is associated with immune mediated side effects, including neurotoxicity. " 01/01/2023 - "CD19-directed chimeric antigen receptor (CAR) T-cell therapy has been widely used and is highly effective for B-cell lymphoid malignancies. "
2.	Hematologic Neoplasms (Hematological Malignancy) 01/01/2017 - "While chimeric antigen receptors (CARs) have been used extensively to redirect the specificity of autologous T cells against hematological malignancies with striking clinical results, studies of CAR-modified natural killer (NK) cells have been largely preclinical. " 10/29/2023 - "Chimeric antigen receptor (CAR) T-cell therapy is an innovative treatment approach that has shown remarkable efficacy against several hematologic malignancies. " 10/01/2023 - "Chimeric antigen receptor (CAR)-T-cell therapies have exhibited remarkable efficacy in the treatment of hematologic malignancies, with 9 CAR-T-cell products currently available. " 01/01/2023 - "Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in treating highly refractory and relapsing hematological malignancies in pediatric and adult patients. " 01/01/2022 - "Chimeric antigen receptor expressing T cells (CAR-T cells) have shown remarkable efficacy against some blood cancers and have potential to treat many other human diseases. "
3.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/01/2023 - "Chimeric antigen receptor T cells targeting CD19 (CART-19) have shown remarkable efficacy for relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (BCP-ALL). " 01/01/2021 - "Chimeric antigen receptor (CAR) T-cells targeting CD19 demonstrate remarkable efficacy in treating B-lineage acute lymphoblastic leukemia (BL-ALL), yet up to 39% of treated patients relapse with CD19(-) disease. " 01/01/2020 - "Chimeric antigen receptor (CAR) T cell therapy, especially anti-CD19 CAR T cell therapy, has shown remarkable anticancer activity in patients with relapsed/refractory acute lymphoblastic leukemia, demonstrating an inspiring complete remission rate. " 12/01/2018 - "Autologous CD19 chimeric-antigen receptor (CAR) T cells demonstrated remarkable remission rates in relapsed and refractory acute lymphoblastic leukemia (R/R ALL). " 10/01/2018 - "Chimeric antigen receptors (CARs) have shown remarkable ability to re-direct T cells to target CD19-expressing tumours, resulting in remission rates of up to 90% in individuals with paediatric acute lymphoblastic lymphoma. "
4.	B-Cell Lymphoma (Lymphoma, B Cell) 03/29/2023 - "Although chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with chemo-refractory B-cell lymphoma, a significant portion is refractory or relapse. " 08/01/2022 - "CD19-directed chimeric antigen receptor T cells (CAR-T) have emerged as a highly efficacious treatment for patients with relapsed/refractory (r/r) B cell lymphoma (BCL). " 01/01/2021 - "The advent of commercially available chimeric antigen receptor (CAR) T-cell therapy in the last three years has dramatically improved the outcomes of patients with R/R large B-cell lymphoma.Areas" 11/23/2022 - "Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. " 12/01/2021 - "Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has significantly improved outcomes in the treatment of refractory or relapsed large B-cell lymphoma (LBCL). "
5.	Leukemia 01/01/2017 - "Recent clinical trials using chimeric antigen receptor (CAR) T-cell therapy to treat patients with leukemia have shown very promising results. " 01/01/2015 - "This is impressively demonstrated by redirecting T cells with a chimeric antigen receptor (CAR) towards CD19, inducing complete and lasting remission of leukemia in more than two-thirds of patients in early phase trials. " 12/01/2019 - "Ninety percent of relapse/refractory B-cell acute lymphatic leukemia (R/R B-ALL) patients can achieve complete remission (CR) after CD19-targeting chimeric antigen receptor T (CAR-T) cell therapy. " 01/01/2017 - "CD19-directed chimeric antigen receptor (CAR) T cells are clinically effective in a limited set of leukemia patients. " 12/01/2022 - "Adaptive CD19-targeted chimeric antigen receptor (CAR) T-cell transfer has become a promising treatment for leukemia. "

Related Drugs and Biologics

1.	Antigens
2.	Immune Checkpoint Inhibitors
3.	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amine
4.	T-Cell Antigen Receptors (T-Cell Receptor)
5.	B-Cell Maturation Antigen
6.	Monoclonal Antibodies
7.	Bispecific Antibodies
8.	tisagenlecleucel
9.	Immunoconjugates (Immunoconjugate)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Cell- and Tissue-Based Therapy (Cell Therapy)
4.	Drug Therapy (Chemotherapy)
5.	Hematopoietic Stem Cell Transplantation